Shots:
- Novartis has entered into an agreement to acquire Tourmaline Bio, incl. its asset pacibekitug, expanding its cardiovascular portfolio
- As per the deal, Novartis, through its subsidiary, will acquire Tourmaline for $48/share, representing an aggregate of ~$1.4B, & will merge the subsidiary into Tourmaline upon completion, making it an indirect wholly owned unit of Novartis; closing expected in Q4’25
- Pacibekitug, a P-III ready anti-IL-6 mAb, reduced median hs-CRP levels by 85% with 15mg dosing (QM) & 86% with 50mg (Q4M) in the P-II (TRANQUILITY) study for atherosclerotic cardiovascular disease
Ref: Novartis | Image: Tourmaline Bio | Press Release
Related News:- Argo Biopharma Inks a ~$5.3B Deal with Novartis for Multiple Cardiovascular Assets, Expanding their Existing Partnership
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
